Sign in
4

Changes in Ownership

Axsome Therapeutics, Inc. Filed Acc 0001193125-25-308354

Chief Executive Officer sold 79,973 shares at an average $145.66 ($11,648,582)

  • Chief Executive Officer acquired 79,973 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

TABUTEAU HERRIOT · Chief Executive Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2025-12-02 Exercise or conversion : show line 1 in the form 10b5-1 +49,252 $8.02 $395,001 56,481 D
2025-12-02 Sale : show line 2 in the form 10b5-1 −49,252 $144.59 $7,121,347 7,229 D
2025-12-03 Exercise or conversion : show line 3 in the form 10b5-1 +20,163 $8.02 $161,707 27,392 D
2025-12-03 Sale : show line 4 in the form 10b5-1 −20,163 $146.94 $2,962,751 7,229 D
2025-12-04 Exercise or conversion : show line 5 in the form 10b5-1 +10,558 $8.02 $84,675 17,787 D
2025-12-04 Sale : show line 6 in the form 10b5-1 −10,558 $148.18 $1,564,484 7,229 D
Open-market sales · 79,973 sh · avg $145.66 · $11,648,582

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2025-12-02 Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (Right to Buy) −49,252 202,545 D
2025-12-03 Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (Right to Buy) −20,163 182,382 D
2025-12-04 Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (Right to Buy) −10,558 171,824 D
Loading xslF345X05/ownership.xml…